הכנסה תפעולית לפני ניכוי פחת: Passage Bio, Inc. (PASG)

Passage Bio, Inc. (PASG) develops gene therapies for rare CNS pathologies by correcting genetic defects in the brain. Patent protection and orphan drug status provide the company with a competitive market advantage. Absolute EBITDA confirms the financial dynamics, where this metric equals 0.00. Growth is expected from GM1 test results and FDA approval of an innovative gene delivery system.

This metric measures the operational efficiency of the business by excluding the impact of depreciation and taxes, allowing for an assessment of the actual cash flow from core operations. By analyzing the EBITDA_Co metric, an investor can compare the capital intensity of developing unique DNA delivery methods to the brain with current returns, assessing the resilience of Passage Bio, Inc. (PASG) amidst the high risks of clinical trials.